Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$41.60
▲ $1.81 (+4.5%)
Market data updated: 09/21 06:18 PM
Fundamentals updated: 09/21/2026
News analyzed: 09/21/2026
Market Cap
$3.34B
Day Range
$39.40 - $41.98
52-Week Range
$29.46 - $60.91
Beta
—
Next Earnings
02.11.2026
Support
$38.24
Resistance
$60.82
VCYT is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+21.5% (1Y)
Strengths: 9/28 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Earnings per share (EPS) growth
Earnings per share (EPS) growth: 164.5%
Growth
Biggest negative driver
DCF Fair Value
Estimated fair value: $36.55 vs. price $41.60 (-12.1%)
Fair Value
Signal tension
Growth scores strong (79/100), but fair-value analysis scores this stock as relatively expensive (33/100) — the growth story and the current price aren't fully aligned.
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
51
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
79
Quality
58
Value
33
Momentum
19
Risk
40
Sentiment
98
Fundamental
59
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
The provided sources do not mention Veracyte, Inc., so there is no recent media coverage available to summarize. No details about the company’s recent activities, events, or themes can be reliably reported based on the given headlines.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Veracyte, Inc.. News trend score: 98. Reason: 12 of the last 20 articles are positive, versus 4 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
19
🎯 Conviction (vs. Emotion)
41
Psychology
41
Fundamentals
59
Technical
19
Valuation
33
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
A significant decline over time, but on unusually low trading volume — holders unwilling to accept the loss.
Extreme momentum, price far above its moving average, and a large premium over fair value.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Price (3M)
-23%
Market Narrative
56
Fundamental Reality
41
Narrative Gap
+15
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
VCYT’s psychology is dominated by **loss aversion**, reflecting a 11.9% drop over three months and muted trading activity. While euphoria and overconfidence are muted by valuation and technical alignment, the narrative gap (56 vs. 41) hints at investors clinging to optimism despite underperformance. The key question: *Will traders exit to lock in gains or hold for recovery?* The absence of panic or FOMO suggests a cautious, risk-averse stance.
Updated: 09/09/2026, 09:32 AM
What could change this?
📈 12D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Walter Bagehot — 100/100
🔴 Weakest match
Benjamin Graham — 26/100
🗣️ Why do they disagree?
The stark divide in methodology verdicts for VCYT reflects deep contrasts in how these investors prioritize risk, growth, and valuation. At the top, Walter Bagehot’s near-perfect score highlights his focus on liquidity and resilience, while Peter Lynch and Charles Mackay see it as a growth stock with no speculative frenzy—aligning with their forward-looking, momentum-driven approaches. Meanwhile, Howard Marks (both cycle and general) leans cautiously optimistic, framing it as mid-cycle rather than overvalued, though his mixed verdict hints at lingering caution. On the other hand, Graham’s methodologies—especially the strict Defensive Investor—reject VCYT outright for lacking statistical safety margins, while Loeb and Livermore flag it as high-risk, clashing with their conservative trend-following and capital-preservation principles. Even moderate voices like Fisher and Schwager acknowledge its merits but temper enthusiasm, suggesting it’s a solid but not exceptional bet, whereas efficient-market theorists dismiss it as unconvincing compared to passive indexing.
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟢 90
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 74
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟢 73
Solid, but not the exceptional quality Fisher looked for
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟢 73
A real, disciplined setup with favorable reward/risk
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 71
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 67
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 57
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 56
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 49
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 46
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 45
Moderate — holdable, but not effortless
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 39
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 34
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🔴 31
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🔴 26
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Based on the last 281 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (1 bullish · 8 bearish · 2 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Low confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
70.1%
Operating Margin
11.2%
Net Margin
12.8%
EBITDA Margin
15.3%
ROE
5.1%
ROA
4.7%
ROIC
—
EPS
$0.84
Cash
$362.58M
Total Debt
—
Current Ratio
8.15
Debt/Equity
—
How is Fair Value calculated? →
Current Price
$41.60
Estimated Fair Value (DCF)
$36.55
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-12.1%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
20.4%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 20.4% | $152.48M | $139.89M |
| 2 | 15.9% | $176.77M | $148.78M |
| 3 | 11.5% | $197.02M | $152.14M |
| 4 | 7.0% | $210.77M | $149.31M |
| 5 | 2.5% | $216.04M | $140.41M |
Base FCF (last actual year)
$126.63M
Terminal Value
$3.41B
Present Value of Terminal Value
$2.21B
Enterprise Value
$2.94B
Net Debt
$0
Equity Value
$2.94B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$16.25
Tangible Book Value per Share (Tangible NAV)
$5.63
Sentiment based on basic keywords (not AI) — 12 positive, 4 neutral, 4 negative out of the last 20 articles.
ChartMill · 21.9.2026
Yahoo · 18.9.2026
Yahoo · 18.9.2026
Yahoo · 18.9.2026
Yahoo · 17.9.2026
Yahoo · 17.9.2026
Yahoo · 17.9.2026
Yahoo · 17.9.2026
Yahoo · 17.9.2026
Yahoo · 16.9.2026
Yahoo · 16.9.2026
Yahoo · 16.9.2026
Yahoo · 16.9.2026
Yahoo · 16.9.2026
Yahoo · 15.9.2026
Yahoo · 15.9.2026
Yahoo · 15.9.2026
Yahoo · 15.9.2026
Yahoo · 15.9.2026
SeekingAlpha · 15.9.2026
Veracyte, Inc. (VCYT) currently has a StockIQ AI score of 51/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
VCYT currently scores 51/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, VCYT's estimated fair value is $36.55, which is 12.1% below the current price of $41.60. This is one valuation model among several signals in the fair-value category, not a price target.
VCYT's technical score is 19/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Earnings per share (EPS) growth: 164.5%; Free cash flow growth: 98.5%; Net income growth: 174.9%.
Based on the real signals StockIQ computed: Estimated fair value: $36.55 vs. price $41.60 (-12.1%); SMA 50 recently crossed below SMA 200; ATR: 5.3% of price.
StockIQ has no recorded dividend payment history for VCYT.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 11 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| McGuire Annie | Open Market Sale | 4.9.2026 | 1,100 | -1,100 | $43.67 |
| Chambers Rebecca | Open Market Sale | 4.9.2026 | 2,477 | -2,477 | $42.81 |
| Febbo Phillip G. | Open Market Sale | 4.9.2026 | 10,405 | -10,405 | $42.89 |
| Chambers Rebecca | Open Market Sale | 4.9.2026 | 1,175 | -1,175 | $43.71 |
| Febbo Phillip G. | Open Market Sale | 4.9.2026 | 2,705 | -2,705 | $43.66 |
| McGuire Annie | Open Market Sale | 4.9.2026 | 2,154 | -2,154 | $42.79 |
| Wygant Jonathan | Tax Withholding in Shares | 2.9.2026 | 1,361 | -1,361 | $44.88 |
| Febbo Phillip G. | Tax Withholding in Shares | 2.9.2026 | 3,639 | -3,639 | $44.88 |
| Leite John | Tax Withholding in Shares | 2.9.2026 | 3,961 | -3,961 | $44.88 |
| McGuire Annie | Tax Withholding in Shares | 2.9.2026 | 3,215 | -3,215 | $44.88 |
| Stapley Marc | Tax Withholding in Shares | 2.9.2026 | 8,782 | -8,782 | $44.88 |
| Chambers Rebecca | Tax Withholding in Shares | 2.9.2026 | 3,603 | -3,603 | $44.88 |
| Bhanji Muna | Open Market Sale | 1.9.2026 | 1,864 | -1,864 | $42.97 |
| EASTHAM KARIN | Open Market Sale | 18.6.2026 | 3,200 | -3,200 | $52.78 |
| EASTHAM KARIN | Open Market Sale | 18.6.2026 | 529 | -529 | $53.55 |
| EASTHAM KARIN | Open Market Sale | 18.6.2026 | 15,626 | -3,200 | $52.78 |
| EASTHAM KARIN | Open Market Sale | 18.6.2026 | 15,097 | -529 | $53.55 |
| Holstein Jens | Grant/Award from Employer | 11.6.2026 | 5,272 | +5,272 | — |
| Shafer David Brent | Grant/Award from Employer | 11.6.2026 | 5,272 | +5,272 | — |
| Barr Eliav | Grant/Award from Employer | 11.6.2026 | 5,272 | +5,272 | — |
| EPSTEIN ROBERT S | Grant/Award from Employer | 11.6.2026 | 5,272 | +5,272 | — |
| JONES EVAN/ FA | Grant/Award from Employer | 11.6.2026 | 5,272 | +5,272 | — |
| EASTHAM KARIN | Grant/Award from Employer | 11.6.2026 | 5,272 | +5,272 | — |
| Miller Thomas F. | Grant/Award from Employer | 11.6.2026 | 5,272 | +5,272 | — |
| Bhanji Muna | Grant/Award from Employer | 11.6.2026 | 5,272 | +5,272 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
8,077,228 shares short as of 2026-08-31 · vs. 6,858,686 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
74.2% of trading volume this week was short selling, vs. 65.3% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology